We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App





Bio-Rad Showcases Comprehensive Range of Quality Control-Related Offerings

By LabMedica International staff writers
Posted on 20 Jul 2023

Bio-Rad Laboratories (Hercules, CA, USA) is showcasing its comprehensive range of quality control-related offerings at the American Association of Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo, AACC 2023, in Anaheim, Calif. More...

, July 23-27. At booth #3239 on the AACC 2023 exhibition floor, attendees can explore and learn about Bio-Rad’s leading QC products, including the new Cardiac Advance product, Exact Diagnostics branded infectious disease molecular quality controls & panels, the family of InteliQ Load-and-Go controls, and Unity Next Peer QC data management solutions.

At the Bio-Rad AACC booth, visitors can explore its new comprehensive, multi-analyte control optimized for high sensitivity Troponin testing. Containing the ten most tested cardiac analytes, Cardiac Advance Control offers a consolidated formula to monitor the precision of cardiac laboratory testing procedures in one comprehensive control. Additionally, Bio-Rad’s InteliQ Load-and-Go controls allow labs to transform their QC workflow with load-and-go efficiency. InteliQ quality controls empower labs by automating workflow - reducing turnaround time, limiting manual errors, and increasing overall efficiency. Visitors to the company’s booth can also learn more about its latest offering, Unity Next Peer QC, which is a simple peer comparison tool with instant access to peer reporting in a centralized, user-friendly platform. Built on the foundation of Unity and supported by comprehensive QC data, Unity Next helps labs confidently make decisions to mitigate QC errors and protect patient safety.

At AACC 2023, Bio-Rad is also demonstrating how to streamline diabetes testing with fast and accurate smart HPLC and perform A1c testing without common hemoglobin variant interference. The company is demonstrating the D-100 hemoglobin testing system, a fully automated, best-in-class HbA1c analyzer for high-volume labs. The D-100 delivers more results with less effort with SMART HPLC, without sacrificing quality or workflow efficiency. In addition, Bio-Rad is demonstrating the BioPlex 2200 System, a fully automated, random-access, track line compatible, multiplex platform. BioPlex 2200 improves turnaround time, throughput, and overall workflow efficiency. With over 50 multiplex assays, the BioPlex System consolidates autoimmune, infectious disease, and vitamin D testing. One of the highlighted events during the conference is Bio-Rad’s industry workshop titled “A New Era in Laboratory Quality – Managing Molecular QC Data.” The workshop aims to provide attendees with valuable insights, including a discussion on molecular QC data management workflow improvements post-Unity implementation, a description of the value of Unity in evaluating the performance of viral load assays, and an identification of three essential functions of Unity for QC data management.

Related Links:
Bio-Rad Laboratories


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.